Search
Now showing items 1-10 of 21
The evolving management of epithelioid sarcoma.
(2021-07-18)
Drug repositioning in sarcomas and other rare tumors.
(ELSEVIER SCIENCE BV, 2016-03-17)
Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma.
(TAYLOR & FRANCIS LTD, 2019-07-03)
Introduction: Liposarcomas (LPS) are a heterogeneous group of adipocytic soft tissue sarcomas with limited treatment options in the advanced/metastatic setting. Pazopanib is a multi-target tyrosine kinase inhibitor (TKI) ...
Olaratumab in soft tissue sarcoma - Current status and future perspectives.
(ELSEVIER SCI LTD, 2018-03-01)
Recent randomised phase II trial data have indicated that the addition of olaratumab, a novel monoclonal antibody against platelet-derived growth factor receptor alpha (PDGFRα), to doxorubicin confers an unprecedented ...
Clinical and Molecular Spectrum of Liposarcoma.
(LIPPINCOTT WILLIAMS & WILKINS, 2018-01-10)
Liposarcomas are rare malignant tumors of adipocytic differentiation. The classification of liposarcomas into four principal subtypes reflects the distinct clinical behavior, treatment sensitivity, and underlying biology ...
The adequacy of tissue microarrays in the assessment of inter- and intra-tumoural heterogeneity of infiltrating lymphocyte burden in leiomyosarcoma.
(NATURE PORTFOLIO, 2019-10-10)
The characterisation and clinical relevance of tumour-infiltrating lymphocytes (TILs) in leiomyosarcoma (LMS), a subtype of soft tissue sarcoma that exhibits histological heterogeneity, is not established. The use of tissue ...
Pazopanib in advanced soft tissue sarcomas.
(NATURE PUBLISHING GROUP, 2019-05-17)
Pazopanib is the first and only tyrosine kinase inhibitor currently approved for the treatment of multiple histological subtypes of soft tissue sarcoma (STS). Initially developed as a small molecule inhibitor of vascular ...
The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib.
(TAYLOR & FRANCIS LTD, 2019-10-30)
Introduction: Tyrosine kinases are key mediators of intracellular signaling cascades and aberrations in these proteins have been implicated in driving oncogenesis through the dysregulation of fundamental cellular processes ...
Fibroblast Growth Factor Receptor (FGFR) Signaling in GIST and Soft Tissue Sarcomas.
(MDPI, 2021-06-17)
Sarcomas are a heterogeneous group of rare malignancies originating from mesenchymal tissues with limited therapeutic options. Recently, alterations in components of the fibroblast growth factor receptor (FGFR) signaling ...
Pharmacotherapy for liposarcoma: current and emerging synthetic treatments.
(FUTURE MEDICINE LTD, 2021-04-21)
Liposarcomas are rare tumors arising from adipocytic tissue and accounting for approximately 15-20% of all soft tissue sarcomas. Liposarcoma can be further classified into histopathological subtypes with variable ...